Dr. Martin Andrew Acquadro, MD DMD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2100 Dorchester Ave, 7th Floor, Dorchester Center, MA 02124 Phone: 617-506-2027 Fax: 617-474-3811 |
Trevor John Szymanski, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-506-4000 |
Nada Arrushdi, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-298-4632 Fax: 617-296-6919 |
A James Epstein, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-298-4632 Fax: 617-296-6919 |
Anitha Sadasivan Dasari, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-298-4632 Fax: 617-296-6919 |
News Archive
Modern Healthcare: "The government's efforts to rein in Medicare fraud and abuse recovered $2.5 billion for the program in fiscal 2009, up 29% from $1.9 billion the previous year, according to a new annual report. ... The $2.5 billion collected in fiscal 2009 is attributed to judgments and settlements in previous years as well as 2009, according to the report of the Health Care Fraud and Abuse Control Program.
The FY12 Appropriations Agreement recently passed by Congress includes reinstatements of bans on the domestic and international use of federal funds for needle-exchange programs, the Haiwai'i News Daily reports.
Food and Drug Administration (FDA) regulators have issued a warning on the blood pressure drug known generically as olmesartan medoxomil. The drug can cause intestinal problems known as spruelike enteropathy, which has side effects including severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization.
A new type of artificial hip, more robust and longer lasting than conventional artificial joints, is to undergo clinical trials and could be available for patients within five years.
Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.
› Verified 8 days ago